{"entity":{"id":"pou2f2","kind":"target","name":"POU2F2","aka":["POU class 2 homeobox 2","POU domain, class 2, transcription factor 2","OCT2","OTF2"],"tldr":"POU2F2 (POU domain, class 2, transcription factor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.","summary":"Transcription factor that specifically binds to the octamer motif (5'-ATTTGCAT-3'). Regulates IL6 expression in B cells with POU2AF1. Regulates transcription in a number of tissues in addition to activating immunoglobulin gene expression.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 4 cohorts (3 activating, 1 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:9213","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9213"},{"label":"UniProt P09086","url":"https://www.uniprot.org/uniprotkb/P09086/entry"},{"label":"NCBI Gene 5452","url":"https://www.ncbi.nlm.nih.gov/gene/5452"},{"label":"Ensembl ENSG00000028277","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000028277"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets","intogen"],"cancers":["non-hodgkin-lymphoma","dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"POU2F2","role":["oncogene-driver","tumour-suppressor","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:9213","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9213","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P09086","url":"https://www.uniprot.org/uniprotkb/P09086/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene POU2F2","url":"https://civicdb.org/features/4411","note":"1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000028277","url":"https://platform.opentargets.org/target/ENSG00000028277/associations","note":"per-cancer scores at or above 0.5: non-Hodgkin lymphoma 0.51 (GraphQL API, CC0)"},{"label":"IntOGen POU2F2","url":"https://www.intogen.org/search?gene=POU2F2","note":"driver in 4 cohorts (Act 3, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"specificity":"tumour-specific","distribution":"one-type","specificityNote":"Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA POU2F2: RNA tissue enriched (lymphoid tissue 47 nTPM); high antibody staining in 2 normal tissues; highest cancer staining lymphoma (3 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Lymphoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"UniProt P09086","url":"https://www.uniprot.org/uniprotkb/P09086/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene POU2F2","url":"https://civicdb.org/features/4411","note":"1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)"},{"label":"IntOGen POU2F2","url":"https://www.intogen.org/search?gene=POU2F2","note":"driver in 4 cohorts (Act 3, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"},{"label":"Human Protein Atlas POU2F2 tissue","url":"https://www.proteinatlas.org/ENSG00000028277-POU2F2/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000028277 associations","url":"https://platform.opentargets.org/target/ENSG00000028277/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:9213","ensembl":"ENSG00000028277","uniprot":"P09086","entrez":"5452","firstDescribed":1988,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Clerc R.G. et al, Genes Dev, 1988, \"The B-cell-specific Oct-2 protein contains POU box- and homeo box-type domains\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/3265124/","biology":"Transcription factor that specifically binds to the octamer motif (5'-ATTTGCAT-3'). Regulates IL6 expression in B cells with POU2AF1. Regulates transcription in a number of tissues in addition to activating immunoglobulin gene expression. Modulates transcription transactivation by NR3C1, AR and PGR. Activates the U2 small nuclear RNA (snRNA) promoter. Location: Cytoplasm; Nucleus (UniProt). Locus 19q13.2 (HGNC).","whereFound":["Non-Hodgkin lymphoma: Open Targets association 0.51 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL)","Diffuse large B-cell lymphoma: CIViC evidence names this disease; IntOGen driver in 2 cohorts (DLBCLNOS)"],"targetClass":"transcription","prevalence":[]},"route":"/targets/pou2f2/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}]}}